Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Daniel P. Petrylak; Philip W. Kantoff; Nicholas J. Vogelzang; Anthony Mega; Mark T. Fleming; Joe Stephenson; Richard C. Frank; Neal D. Shore; Robert Dreicer; Edward F. McClay; William R. Berry; Manish Agarwal; Vincent A. DiPippo; Yakov Rotshteyn; Nancy Stambler; William C. Olson; Stephen Morris; Robert J. Israel

doi:10.1002/pros.23765

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In an extensively pretreated mCRPC population, PSMA ADC demonstrated acceptable toxicity. Antitumor activity was observed over dose ranges up to and including 2.5 mg/kg. The observed anti-tumor activity supported further evaluation of this novel agent for the treatment of advanced metastatic prostate cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Petrylak et al. (2019) studied this question.

synapsesocial.com/papers/69d776f55f9a1dad5349047d https://doi.org/10.1002/pros.23765

View at Publisher

Ask AI

Bookmark

Share

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading